Evaluate the effect of TECAR therapy on pain, voiding, erectile function, sleep quality and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome.

Sixty men with chronic prostatitis/chronic pelvic pain will be sourced from the urology outpatient clinic at Tanta University hospitals in Egypt, with referrals from urologists. Patients will be randomly assigned into two groups.

Study group: It will include 30 men receiving true TECAR therapy plus dietary and life style adjustments.

Control group: It will include 30 men receiving sham TECAR therapy plus dietary and life style adjustments.

Evaluation Procedures:

1. Pain, voiding, and quality of life using the National Institutes of Health-Chronic Prostatitis Symptom Index.
2. Sleep quality using the Pittsburgh Sleep Quality Index.
3. Erectile function using the International Index of Erectile Function.

Inclusion Criteria:

• Presence of chronic prostatitis/chronic pelvic pain symptoms for more than 6 months.
• Ages will be ranged from 30 to 50 years old.

Exclusion Criteria:

1. Urinary and seminal infections.
2. Recent parenteral steroid administration.
3. Prior prostate or pelvic surgery.
4. Lower urinary tract disorders such as bladder stones.
5. Implanted electronic devices as pacemakers.
6. Sensory loss over the perineum.